San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, ... to make more than $700 million this year on weight-loss services, a target that could be difficult to reach without Wegovy sales.

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...